FACULDADE DE MEDICINA
UNIVERSIDADE DO PORTO

MESTRADO INTEGRADO EM MEDICINA

2014/2015

Mariana Marques Barbosa

Neonatal pleural effusions in a level III Neonatal Intensive Care Unit

março, 2015

FACULDADE DE MEDICINA
UNIVERSIDADE DO PORTO

Mariana Marques Barbosa

Neonatal pleural effusions in a level III Neonatal Intensive Care Unit

Mestrado Integrado em Medicina

Área: Neonatologia

Tipologia: Dissertação

Trabalho efetuado sob a Orientação de:

Doutora Maria Hercília Ferreira Guimarães Pereira Areias

E sob a Coorientação de:

Dr. Gustavo Marcondes Duarte Rocha

Trabalho organizado de acordo com as normas da revista:

Journal of Pediatric and Neonatal Individualized Medicine

março, 2015

U.PORTO
FMUP FACULDADE DE MEDICINA UNIVERSIDADE DO PORTO
UNIDADE CURRICULAR PROJETO DE OPÇÃO DISSERTAÇÃO / MONOGRAFIA

Projeto de Opção do 6º ano - DECLARAÇÃO DE INTEGRIDADE

Eu, Mariana Marques Barbosa, abaixo assinado, nº mecanográfico 200904833, estudante do 6º ano do Ciclo de Estudos Integrado em Medicina, na Faculdade de Medicina da Universidade do Porto, declaro ter atuado com absoluta integridade na elaboração deste projeto de opção.

Neste sentido, confirmo que **NÃO** incorri em plágio (ato pelo qual um indivíduo, mesmo por omissão, assume a autoria de um determinado trabalho intelectual, ou partes dele). Mais declaro que todas as frases que retirei de trabalhos anteriores pertencentes a outros autores, foram referenciadas, ou redigidas com novas palavras, tendo colocado, neste caso, a citação da fonte bibliográfica.

Faculdade de Medicina da Universidade do Porto, 09/03/2015

Assinatura conforme cartão de identificação:

Mariana Marques Barbosa

U.PORTO
FMUP FACULDADE DE MEDICINA UNIVERSIDADE DO PORTO
UNIDADE CURRICULAR PROJETO DE OPÇÃO DISSERTAÇÃO / MONOGRAFIA

Projecto de Opção do 6º ano – DECLARAÇÃO DE REPRODUÇÃO

NOME

Mariana Marques Barbosa

CARTÃO DE CIDADÃO OU PASSAPORTE (se estrangeiro)	E-MAIL	TELEFONE OU TELEMÓVEL
13858132	marianamb013@gmail.com	961646432

NÚMERO DE ESTUDANTE	DATA DE CONCLUSÃO
200904833	2015

DESIGNAÇÃO DA ÁREA DO PROJECTO

Neonatologia

TÍTULO DISSERTAÇÃO/~~MONOGRAFIA~~ (riscar o que não interessa)

Neonatal pleural effusions in a level III Neonatal Intensive Care Unit

ORIENTADOR

Maria Hercília Ferreira Guimarães Pereira Areias

COORIENTADOR (se aplicável)

Gustavo Marcondes Duarte Rocha

É autorizada a reprodução integral desta Dissertação/~~Monografia~~ (riscar o que não interessa) para efeitos de investigação e de divulgação pedagógica, em programas e projectos coordenados pela FMUP.

Faculdade de Medicina da Universidade do Porto, 09/03/2015

Assinatura conforme cartão de identificação: Mariana Marques Barbosa

Neonatal pleural effusions in a level III Neonatal Intensive Care Unit

Mariana Barbosa[1], Gustavo Rocha[2], Filipa Flôr-de-Lima[2] and Hercília Guimarães[1,2]

[1] Faculty of Medicine of Porto University, Porto, Portugal

[2] Department of Pediatrics, Division of Neonatology, Hospital de São João, Porto, Portugal

Correspondence: Mariana Barbosa, Faculty of Medicine of Porto University, Hospital de São João — Alameda Prof. Hernâni Monteiro, 4202–451 Porto, Portugal.

E-mail: marianamb013@gmail.com

Abstract

Pleural effusions are rare in the newborn. Still, being familiar with this condition is relevant given its association with a wide range of disorders. Only two large series of cases on this matter have been published, with no solid conclusions established. The aim of this study is to determine the etiology, management and prognosis of pleural effusions in a population of high-risk neonates.

The authors performed a retrospective study in the Neonatal Intensive Care Unit of Hospital de São João, Porto, between 1997 and 2014, of all newborns with the diagnosis of pleural effusion, chylothorax, hemothorax, empyema, fetal hydrops or leakage of total parenteral nutrition.

Eighty-two newborns were included, 48 males and 34 females. Pleural effusions were congenital in 19 (23.2%) newborns and acquired in 63 (76.8%). Fetal hydrops was the most frequent cause (15 cases, 78.9%) of congenital effusions while postoperative after intrathoracic surgery was the most common cause (39 cases, 61.9%) of acquired effusions, followed by leakage of total parenteral nutrition (13 cases, 20.6%). Chylothorax was the most common type of effusion (41.5% of cases). Pleural effusions after intrathoracic surgery were mainly (64.1%) chylothoraces. Regarding use of octreotide for treatment of chylous effusions, the comparative analysis showed no statistical differences between the group of alive newborns who received octreotide and the group who did not. Twenty-seven (32.9%) newborns died; the causes of death were related to underlying diseases and not to the pleural effusion. Clinical outcome is generally good, except in hydropic neonates. Blood albumin level appears to be predictive of prognosis and further investigation on its clinical significance should be encouraged.

Key-words

Pleural effusion, newborn, chylothorax, hydrops fetalis, serum albumin, prognosis

Introduction

The pleural space exists between the parietal pleura of the chest wall and the visceral pleura of the lung. Both pleural surfaces filter fluid into the pleural space and the lymphatics are responsible for most of the fluid reabsorption [1]. Pleural effusion, defined as fluid accumulation in the pleural space, can occur if the rate of filtration increases, or if the rate of lymphatic clearance decreases, or if both of these mechanisms are present [2].

Pleural effusions are rare in the neonate [3]. Nevertheless, being familiar with this condition is relevant because of its generally favorable prognosis [4]. Effusions may be diagnosed antenatally or they can appear at any time during the neonatal period. They may be asymptomatic or present with respiratory distress [2].

Several causes have been described in the literature, including congenital and acquired chylothoraces, fetal hydrops, and parapneumonic effusions [4]. There are also reports of hemothorax and leakage of parenteral nutrition, which are usually iatrogenic complications [3, 5]. Still, information on the relative frequencies of these disorders as causes of pleural effusions is sparse.

Treatment options and clinical outcomes are also poorly described. Guidelines for management of pediatric chylothorax have been proposed [6, 7] but only one publication presents specific guidelines for the neonatal period [8]. Moreover, new therapeutic approaches have been developed and no prospective or randomized trials have yet been performed [9].

There are only two recent publications reporting large series of pleural effusions in the fetus and newborn and no solid conclusions have been established so far [3, 10]. Therefore, the aim of this study is to investigate etiology, clinical management and prognosis of neonatal pleural effusions in a tertiary neonatal intensive care unit (NICU).

Material and methods

All newborns admitted to the NICU of Hospital de São João, Porto, between 1997 and 2014, with the discharge diagnosis of pleural effusion, chylothorax, hemothorax, empyema, fetal hydrops or leakage of total parenteral nutrition (TPN) were included. Our NICU is a level III unit and a reference center for cardiothoracic surgery. All the data were obtained by a retrospective search from the hospital computer database and medical records.

Demographic data and information regarding pregnancy and delivery were recorded. Pleural effusion characteristics were also collected: congenital or acquired, laterality, volume, clinical presentation, other associated effusions, prenatal diagnosis, gestational age at diagnosis, duration of the effusion and biochemical, cytological and bacteriological analysis of the fluid. In addition, data regarding treatment and neonatal morbidity and mortality were collected.

Pleural effusions were diagnosed by chest radiography (standard supine anteroposterior projection) and/or chest ultrasound and classified as: small – if they were apparent in not more than a quarter lung field; moderate – if apparent in a quarter to half lung field; large – if apparent in more than half lung field; massive – if apparent around the entire lung with mediastinal shift [3]. Type of effusion was assessed based on biochemical and cytological analysis of the fluid. Etiology of the effusion was established according to the clinical setting and medical history.

Chylothorax was defined according to the criteria proposed by Buttiker et al: an absolute white cell count >1000 cells/μL with a lymphocyte fraction >80% and triglyceride levels >110 mg/dL in pleural fluid (provided there was minimal fat enteral intake) [6] and treated according to the published guidelines [8]. Transudates were effusions with a total protein level <3.0 g/dl or a pleural/serum protein ratio <0.5, and a total leukocyte count <1000/mm^3 with predominance of mononuclear cells. Exudate was defined by the presence of at least one of the following: protein level >3.0 g/dl with pleural/serum protein ratio >0.5; pleural fluid lactic dehydrogenase (LDH) values >200 IU/L; or a pleural-to-serum LDH ratio >0.6 [11]. Empyema was defined as an exudative effusion presenting with purulent appearance and a total leukocyte count >5000/mm^3 with predominance of polymorphonuclear cells (PMNs). Hemothorax was diagnosed based on the presence of blood in the pleural space [11]. Leakage of TPN was considered in neonates with a central venous catheter that presented a pleural fluid with a low leukocyte count and high concentrations of both glucose and potassium [5].

Fetal hydrops was defined as an excessive fluid accumulation within the fetal extravascular compartments and body cavities, characterized by generalized skin thickness of >5 mm, placental enlargement, pericardial or pleural effusion, or ascites [12].

Gestational age was assessed by post-menstrual age, ultrasound examination [13] or the New Ballard Score (in the absence of obstetrical indexes) [14]. Small for gestational age was defined as a birth weight below 3rd percentile of Fenton's fetal growth charts [15].

Hyaline membrane disease was defined based on the european guidelines [16]. The diagnosis of bronchopulmonary dysplasia was made according to the NIH Consensus definition [17]. Hemodynamically significant patent ductus arteriosus was diagnosed according to SIBEN consensus [18]. The diagnosis and staging of necrotizing enterocolitis was established based on Bell criteria [19]. Intraventricular hemorrhage was classified according to Papile [20] (before 2010) and Volpe [21] (after 2010). Cystic periventicular leukomalacia was classified according to de Vries and Rennie [22]. Staging of retinopathy of prematurity was done according to the international classification [23]. Proven neonatal sepsis was defined as any systemic infection documented by a positive blood culture. Pneumonia was diagnosed based on clinical, radiological and bacteriological parameters. Hypoalbuminemia was defined by a blood albumin level < 35 g/L [2].

The statistical analysis was performed using SPSS for Windows, version 20. Continuous variables were characterized by mean (± standard deviation) or median (medium-maximum) if they had symmetric or asymmetric distribution respectively and categorical variables by absolute and relative frequencies. To compare continuous variables non-parametric tests (Mann Whitney-U test or Kruskal Wallis test) were used if they had two or more than two categories, and Chi-Squared or Fisher's exact test to compare categorical variables, the latter for expected

values less than 5. A multivariate analysis by logistic regression was performed to evaluate predictive factors for death. A p value less than 0.05 was considered statistically significant.

Results

During the 18 years of the study period, about 7200 newborns were admitted to the NICU and 82 neonates with pleural effusion were retrieved and studied. The incidence of effusions in our series was 110 per 10000 neonates. Demographic and clinical data are summarized in Table 1. Pleural effusions were congenital in 19 (23.2%) neonates and acquired in 63 (76.8%). The etiologies of each category are described in Table 2.

We observed 15 cases of congenital pleural effusion with fetal hydrops. Five (33.3%) of them were chylothoraces, nine (60%) were transudates and one (6.7%) was of unknown type. Out of the nine transudates, five (55.6%) were caused by fetal arrhythmia, one (11.1%) by twin-to-twin transfusion syndrome, one (11.1%) by hemochromatosis, one (11.1%) by congenital nephrotic syndrome and one (11.1%) was idiopathic.

Regarding acquired effusions, 39 (61.9%) were iatrogenic after intrathoracic surgery. The association was found for surgical interventions on three types of major congenital malformations: congenital heart disease (CHD), diaphragmatic hernia and esophageal atresia. These postoperative effusions were chylothoraces in 25 (64.1%) cases.

Extravasation of TPN was identified in 13 newborns (20,6% of the acquired effusions). They were unilateral in eight (61.5%) cases and of moderate volume in five (38.5%). Four of them had spontaneous resolution of the effusion after catheter removal, with no need for further intervention. The median duration of effusions in this group was 2 days (range, 1-6 days). Two of the newborns died.

Three newborns developed parapneumonic effusions; fluid analysis was consistent with empyema in all of them.

Of the three cases of hemothorax, one was congenital and occurred in a newborn with a paravertebral neuroblastoma associated with disseminated intravascular coagulation. The other two were acquired; one in a newborn performing anticoagulation therapy for extracorporeal membrane oxygenation (ECMO) and the other as a complication of cardiac catheterization with pulmonary hemorrhage. In this group the median duration of the effusions was 2 days (range, 1-14 days) and all of them died.

Chylothorax was the diagnosed type of effusion in 34 (41.5%) neonates. Other types were: 23 (28.0%) transudates, seven (8.5%) exudates, 13 (15.9%) cases of fluid consistent with TPN, three (3.7%) cases of fluid consistent with blood (hemothorax) and two (2.4%) unknown. Table 3 shows pleural effusion characteristics and demographic/clinical data of the three major types.

Chylous effusions are described in more detail in Table 4. Twelve neonates with chylothorax were treated with octreotide; five of them died. The comparative analysis of clinical outcomes in both congenital and acquired chylous effusions showed no statistical differences between the group of alive newborns who received octreotide and the group who did not.

In this series, 27 (32.9%) newborns died (nine in the group of congenital effusions and 18 in the group of acquired effusions). The causes of death were related to the underlying disease and not to the pleural effusion. The analysis of predictor factors for death showed that higher blood levels of albumin are protective (OR 0.912; 95% CI 0.85-0.98); a blood albumin level $\leq$ 12.1 g/L had a sensitivity of 81.5% for mortality.

Discussion

The 82 cases of neonatal pleural effusions identified in our study are representative of 18 years of retrospective investigation, which is longer than any other series described. Our estimated effusions' incidence, 110 per 10000 admissions, is according to the literature (from 5.5 to 220 per 10000 admissions) [3, 24]. In our study there were no significant differences between gender, although pleural effusions occurred more commonly in males as described in previous reports [2].

Etiology and management

As described in Table 2, acquired effusions were more common than congenital ones, comprising about three-quarter of the cases. Regarding congenital effusions, fetal hydrops was the most frequent etiology and transudate was the most frequent type. Concerning acquired effusions, postoperative after intrathoracic surgery was the most common etiology and chylothorax was the most common type.

Comparing the three major types of effusion (Table 3), the preponderance of acquired effusions is observed in all of them. Apgar scores appeared to be lower immediately after birth, with slight recovery at 5^{th} minute, and none of the exudates had low scores; this is probably related to the morbidity caused by congenital effusions at birth. Associated effusions in other cavities, namely ascites and subcutaneous edema, were especially found in transudates, probably dependent on the cases of fetal hydrops. About associated malformations, transudates were particularly found in diaphragmatic hernias, possibly because of physiological disturbances of fluid regulation following surgical repair of the hernia sac. On the other hand, chylothoraces were more commonly associated to CHD, probably because of postoperative effusions. In fact, postoperative effusions were mainly chylous. There were also differences on treatment modalities between types: although thoracocentesis was equally performed, chest tube drainage was particularly used in chylothoraces while diuretic therapy was a frequent option for transudates. As expected, octreotide, medium-chain triglycerides (MCT) and thoracic duct ligation were only used in chylothoraces.

Chylous effusions

Chylothorax is a rare cause of respiratory distress in the newborn and the most common form of pleural effusion in the neonatal period [25]. In fact, chylothorax was the most common type of effusion (41.5%) in this study. It is defined by the accumulation of chyle in the pleural space [6] and some authors distinguish three subtypes according to its cause: congenital, traumatic and nontraumatic [4, 6, 25].

Congenital chylothorax

The etiology of congenital chylothorax is not well understood, but it is thought to occur secondary to trauma to the thoracic duct during delivery or a congenital malformation of the lymphatic vessels [26].

All congenital chylothoraces in our study were bilateral, with lower apgar scores at 5^{th} minute and occasional need for immediate thoracocentesis in the delivery room, confirming that these were high-risk and unstable neonates with associated morbidities, namely fetal hydrops. In fact, in our series congenital chylothorax was associated with hydrops in 71.4% of the cases, as already reported in other publications [3]. Congenital chylothorax has also been associated with genetic diseases such as Noonan, Down's and Turner syndromes, and primary congenital pulmonary lymphangiectasis [27] but this association was not found in our series.

The management of this effusion starts from the antenatal period [26]. In our series, 42.9% of these infants had some in utero intervention (two pleuro-amniotic shuntings and one pleural

drainage during amniocentesis); the therapeutic benefit of antenatal drainage relates to resolution of fetal hydrops and prevention of pulmonary hypoplasia and intrauterine fetal death [27]. In our study, thoracocentesis was the preferred strategy in postnatal management. Octreotide was used in two cases and both of them died because of other morbidities. The published reports about octreotide efficacy in congenital effusions have showed mixed success: Shah et al observed good results [9] while Horvers et al found no clear and consistent effect [28]. Both series highlight the need of a randomized controlled trial for further investigation.

Acquired chylothorax

Traumatic chylothorax in the neonate is in most cases iatrogenic after intra-thoracic surgery [25]. It may also occur following the use of ECMO catheters or insertion of chest tubes too far for the treatment of pneumothorax [2]. In our study, the majority of acquired chylothoraces were indeed postoperative (92.6%); we also report one case of complication after pneumothorax drainage (3.7%). The non-traumatic form is extremely rare in the neonatal period and it is caused by an obstruction of the thoracic duct by intra-thoracic tumors, inflammatory diseases or mediastinal lymphangiomatosis [25]. In our series, we report one case of compression by a cervical teratoma (3.7%).

In this study, acquired chylothoraces were mainly unilateral, left-sided and of moderate volume. Postoperative effusions were particularly relevant, as reported in other series [3, 10]. This association was stronger for CHD interventions once 52.0% of the postoperative chylothoraces occurred following cardiac surgery, as supported by published data [29]. Chylothoraces after surgery on diaphragmatic hernias and esophageal atresias have been described [30, 31] but in this study they were less common (24.0% each).

Regarding treatment, these patients had increasing therapeutic needs and required a longer NICU stay. Two neonates required surgical management with thoracic duct ligation due to failure of medical therapy; no complications were registered.

Octreotide has been used in postoperative chylothoraces with promising results [32]. Although a published series presented poor outcomes [30] and despite the significant heterogeneity of case reports, a recent review concluded that octreotide is relatively safe, and may reduce complications in these patients; a randomized trial is again proposed [32]. In this series, octreotide was used in 10 patients and no significant effects were observed.

Fetal hydrops

In this study, the majority of congenital pleural effusions (78.9%) occurred as nonimmune fetal hydrops (NIFH). In fact, NIFH is an important documented cause of congenital pleural effusion [3]. In our study, cardiovascular disorders and lymph vessel dysplasia (congenital chylothorax) were the two major causes of NIFH and they were equally relevant, each one accounting for one third of the hydrops cases. These etiologies are consistent with previous reports, although their relative frequency varies in the literature. Bellini et al described cardiovascular diseases as the predominant cause (21.7%) [12], while Takci et al reported lymphatic dysplasia as the most common diagnosis (23.5%) [33].

Despite the advances in diagnosis and management, NIHF still presents a high mortality rate (40-50%) [34]. In our series, the mortality rate in hydropic neonates was 53.3%. Huang et al found that hydrops resulting from lymphatic dysplasias had a more favorable outcome [34]; that association was not found in our sample.

Leakage of total parenteral nutrition

Extravasation of parenteral fluid as a complication of central venous catheter use is rare [10]; still, it should be considered in any neonate who develops a pleural effusion while receiving a

central venous infusion. An important differential in these cases is chylothorax due to thoracic duct injury during central line insertion [35]; biochemical analysis of the fluid allows the diagnostic distinction [5].
In our study, leakage of TPN constituted a relevant etiology, being the second most common cause of acquired effusions. All these neonates had percutaneously inserted central venous catheters (PICC). TPN effusions were mostly unilateral (61.5%), which is consistent with previous findings [3]. The resolution of the effusion was fastest in these cases because there was prompt removal of the triggering agent (catheter) and discontinuation of TPN infusion.

Pneumonia

Pneumonias can complicate with the spreading of bacterial infection within the thoracic cavity, resulting in pleural effusions, usually empyemas. *Staphylococcus aureus*, *Streptococcus pneumoniae* and *Streptococcus pyogenes* are the most common causes [11]; other agents, like *Bacteroides fragilis* and *Acinetobacter calcoaceticus*, have also been reported [3, 24]. Out of the three empyemas diagnosed in our series, one case was secondary to meconium aspiration syndrome and the other two were caused by *Acinetobacter* and *Enterobacter aerogenes*.

Hemothorax

Hemothorax most commonly occurs after chest trauma; it is also an occasional manifestation of blood dyscrasias, intrathoracic neoplasms, thrombolytic therapy, and iatrogenic erosion of vessels by surgical procedures [11]. The three cases of hemothorax found in our series had a fatal outcome. Still, no prognostic conclusions can be assessed given the limited number of cases.

Prognosis

The mortality rate was relevant (32.9%) but none of the deaths was directly related to the effusion. There are reports of patients dying because of pulmonary hypoplasia related to congenital effusions [3] but this association was not found in our sample. In this study, the major causes of mortality were multiorganic failure, sepsis and extensive hemorrhagic disorders.
From all the variables studied, only blood albumin levels were predictive of prognosis: lower levels were associated to death in both chylous and non-chylous effusions. According to this, we speculated that hypoalbuminemia may reflect worst clinical condition of the patient. Although hypoalbuminemia was already described as a common complication of congenital chylothoraces [27], no information on its prognostic significance in neonatal effusions is reported in the literature. Further investigation on this matter should be encouraged in order to assess if blood albumin levels could become an analytic marker of prognosis in these patients.

Conclusion

Pleural effusions are rare in the neonate and can be associated with several clinical conditions. Acquired effusions are more common than the congenital forms, which present as fetal hydrops in most of the cases. Traumatic chylothorax after intrathoracic surgery is the major cause of acquired effusions. Prompt diagnosis and adequate management are crucial. Blood albumin levels appear to be predictive of prognosis but further investigation on this matter should be encouraged. Clinical outcome is generally good, except in hydropic neonates.

Funding: None
Conflict of interest: None

References

1. Wiener-Kronish JP, Berthiaume Y, Albertine KH. Pleural effusions and pulmonary edema. Clin Chest Med. 1985;6(3):509-19.
2. Taeusch HW, Ballard RA, Gleason CA. Avery's diseases of the newborn. 8th ed. Philadelphia: Elsevier Saunders; 2005. xxiii, 1633 p., 16 p. of plates p.
3. Rocha G, Fernandes P, Rocha P, Quintas C, Martins T, Proenca E. Pleural effusions in the neonate. Acta Paediatr. 2006;95(7):791-8.
4. Rocha G. Pleural effusions in the neonate. Curr Opin Pulm Med. 2007;13(4):305-11.
5. Wolthuis A, Landewe RB, Theunissen PH, Westerhuis LW. Chylothorax or leakage of total parenteral nutrition? Eur Respir J. 1998;12(5):1233-5.
6. Buttiker V, Fanconi S, Burger R. Chylothorax in children: guidelines for diagnosis and management. Chest. 1999;116(3):682-7.
7. Soto-Martinez M, Massie J. Chylothorax: diagnosis and management in children. Paediatr Respir Rev. 2009;10(4):199-207.
8. Rocha G, Guerra P, Azevedo I, Guimaraes H. [Chylothorax in the fetus and the neonate--guidelines for treatment]. Revista portuguesa de pneumologia. 2007;13(3):377-81.
9. Shah D, Sinn JK. Octreotide as therapeutic option for congenital idiopathic chylothorax: a case series. Acta Paediatr. 2012;101(4):e151-5.
10. Shih YT, Su PH, Chen JY, Lee IC, Hu JM, Chang HP. Common etiologies of neonatal pleural effusion. Pediatr Neonatol. 2011;52(5):251-5.
11. Kliegman R, Nelson WE. Nelson textbook of pediatrics. 18th ed. Philadelphia: Saunders; 2007. lii, 3147 p. p.
12. Bellini C, Hennekam RC, Fulcheri E, Rutigliani M, Morcaldi G, Boccardo F, Bonioli E. Etiology of nonimmune hydrops fetalis: a systematic review. Am J Med Genet A. 2009;149A(5):844-51.
13. MacDonald H, American Academy of Pediatrics. Committee on F, Newborn. Perinatal care at the threshold of viability. Pediatrics. 2002;110(5):1024-7.
14. Ballard JL, Khoury JC, Wedig K, Wang L, Eilers-Walsman BL, Lipp R. New Ballard Score, expanded to include extremely premature infants. J Pediatr. 1991;119(3):417-23.
15. Fenton TR. A new growth chart for preterm babies: Babson and Benda's chart updated with recent data and a new format. BMC Pediatr. 2003;3:13.
16. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, Saugstad OD, Simeoni U, Speer CP, Vento M, Halliday HL, European Association of Perinatal M. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants--2013 update. Neonatology. 2013;103(4):353-68.
17. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723-9.
18. Golombek SG, Sola A, Baquero H, Borbonet D, Cabanas F, Fajardo C, Goldsmit G, Lemus L, Miura E, Pellicer A, Perez JM, Rogido M, Zambosco G, van Overmeire B, Primer Grupo de Consenso Clinico S. [First SIBEN clinical consensus: diagnostic and therapeutic approach to patent ductus arteriosus in premature newborns]. Anales de pediatria. 2008;69(5):454-81.
19. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am. 1986;33(1):179-201.
20. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978;92(4):529-34.
21. Volpe JJ. Neurology of the newborn. 4th ed. Philadelphia: W.B. Saunders; 2001. xiii, 912 p. p.
22. Rennie JM RN. Textbook of Neonatology. 3th ed. London: Churchill Livingstone; 1999.
23. International Committee for the Classification of Retinopathy of P. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123(7):991-9.

24. Long WA, Lawson EE, Harned HS, Jr., Kraybill EN. Pleural effusion in the first days of life: a prospective study. Am J Perinatol. 1984;1(2):190-4.
25. van Straaten HL, Gerards LJ, Krediet TG. Chylothorax in the neonatal period. Eur J Pediatr. 1993;152(1):2-5.
26. Gaede C. Congenital chylothorax: a case study. Neonatal Netw. 2006;25(5):371-81.
27. Downie L, Sasi A, Malhotra A. Congenital chylothorax: associations and neonatal outcomes. J Paediatr Child Health. 2014;50(3):234-8.
28. Horvers M, Mooij CF, Antonius TA. Is octreotide treatment useful in patients with congenital chylothorax? Neonatology. 2012;101(3):225-31.
29. Biewer ES, Zurn C, Arnold R, Glockler M, Schulte-Monting J, Schlensak C, Dittrich S. Chylothorax after surgery on congenital heart disease in newborns and infants -risk factors and efficacy of MCT-diet. J Cardiothorac Surg. 2010;5:127.
30. Gonzalez R, Bryner BS, Teitelbaum DH, Hirschl RB, Drongowski RA, Mychaliska GB. Chylothorax after congenital diaphragmatic hernia repair. J Pediatr Surg. 2009;44(6):1181-5; discussion 5.
31. Dhua AK, Ratan SK, Aggarwal SK. Chylothorax after Primary Repair of Esophageal Atresia with Tracheo-esophageal Fistula: Successful Management by Biological Fibrin Glue. APSP journal of case reports. 2012;3(3):16.
32. Moreira-Pinto J, Rocha P, Osorio A, Bonet B, Carvalho F, Duarte C, Oliveira L. Octreotide in the treatment of neonatal postoperative chylothorax: report of three cases and literature review. Pediatr Surg Int. 2011;27(8):805-9.
33. Takci S, Gharibzadeh M, Yurdakok M, Ozyuncu O, Korkmaz A, Akcoren Z, Yigit S. Etiology and outcome of hydrops fetalis: report of 62 cases. Pediatr Neonatol. 2014;55(2):108-13.
34. Huang HR, Tsay PK, Chiang MC, Lien R, Chou YH. Prognostic factors and clinical features in liveborn neonates with hydrops fetalis. Am J Perinatol. 2007;24(1):33-8.
35. Flannigan C, Bourke T, Keown K, Terris M. Bilateral total parenteral nutrition pleural effusions in a 5-week-old male infant. BMJ Case Rep. 2012;2012.

Tables

Table 1 – Demographic and clinical data of the newborns with pleural effusion (n=82)

Gender, n (%)	
Male	48 (58.5)
Female	34 (41.5)
Birth weight (grams), mean (±SD)	2476 (±941)
Small for gestational age, n (%)	9 (11.0)
Gestational age (weeks), mean (±SD)	35 (±4.3)
Surveillance during pregnancy, n (%)	81 (98.8)
Parity, n (%)	
Single	72 (87.8)
Multiple	10 (12.2)
Prenatal period	
Steroids use, n (%)	27 (32.9)
Full cycle	16 (59.3)
Polyhydramnios	16 (19.5)
Fetal hydrops	15 (18.3)
Delivery, n (%)	
Vaginal	25 (30.5)
C-section	57 (69.5)
Apgar score, n (%)	
1^{st} minute < 7	39 (48.1)
5^{th} minute < 7	21 (26.3)
Resuscitation, n (%)	45 (61.6)
Endotracheal tube	42 (93.3)
Associated congenital malformations, n (%)	53 (65.5)
Chromosomopathy, n (%)	4 (8.0)
Dysmorphic syndrome, n (%) [a]	4 (5.0)
NICU stay (days), median (min-max)	26 (0-167)
Deceased, n (%) [b]	27 (32.9)
Autopsy	19 (70.4)

NICU – Neonatal Intensive Care Unit

[a] Down's syndrome (2), DiGeorge syndrome (1), Klippel-Feil syndrome (1)

[b] multiorganic failure (8), sepsis (7), extensive hemorrhagic disorders (6), congestive heart failure (2), pulmonary hypoplasia (2), fetal arrhythmia (1), alveolar capillary dysplasia (1)

Table 2 – Etiologies and types of pleural effusions

Etiology, n (%)		Type, n (%)					
		Chy	Trans	Exu	TPN	Hem	Unk
Congenital	**19 (23.2)**	**7 (36.8)**	**10 (52.6)**	**0**	**0**	**1 (5.3)**	**1 (5.3)**
Fetal hydrops	15 (78.9)	5 (71.4)	9 (90)	-	-	-	1 (100)
Isolated congenital chylothorax	2 (10.5)	2 (28.6)	-	-	-	-	-
Congestive heart failure	1 (5.3)	-	1 (10)	-	-	-	-
Coagulopathy and intrathoracic neoplasm	1 (5.3)	-	-	-	-	1 (100)	-
Acquired	**63 (76.8)**	**27 (42.9)**	**13 (20.6)**	**7 (11.1)**	**13 (20.6)**	**2 (3.2)**	**1 (1.6)**
Postoperative (after intrathoracic surgery)	39 (61.9)	25 (92.6)	9 (69.2)	4 (57.1)	-	1 (50)	-
Congenital heart disease	15 (38.5)	13 (52.0)	-	1 (25.0)	-	1 (100)	-
Congenital diaphragmatic hernia	16 (41.0)	6 (24.0)	9 (100)	1 (25.0)	-	-	-
Esophageal atresia	8 (20.5)	6 (24.0)	-	2 (50.0)	-	-	-
Leakage of total parenteral nutrition	13 (20.6)	-	-	-	13 (100)	-	-
Pneumonia	3 (4.7)	-	-	3 (42.9)	-	-	-
Compression by intrathoracic tumor	1 (1.6)	1 (3.7)	-	-	-	-	-
Complication of pneumothorax drainage	1 (1.6)	1 (3.7)	-	-	-	-	-
Superior vena cava syndrome	1 (1.6)	-	-	-	-	-	1 (100)
Coagulopathy by thrombolytic therapy	1 (1.6)	-	-	-	-	1 (50)	-
Nephrotic syndrome	1 (1.6)	-	1 (7.7)	-	-	-	-
Congestive heart failure and hypoproteinemia	1 (1.6)	-	1 (7.7)	-	-	-	-
Congestive heart failure and nephrotic syndrome	1 (1.6)	-	1 (7.7)	-	-	-	-
Unknown	1 (1.6)	-	1 (7.7)	-	-	-	-

Chy – chylothorax; Trans – transudate; Exu – exudate; TPN – Total parenteral nutrition; Hem – hemothorax; Unk – unknown

Table 3 – Pleural effusion characteristics and demographic/clinical data according to type

	Chylothorax (n=34)	Transudate (n=23)	Exudate (n=7)	P
Gender, n (%)				
Male	24 (70.6)	15 (65.2)	5 (71.4)	0.925*
Female	10 (29.4)	8 (34.8)	2 (28.6)	
Gestational age at birth (weeks), median (min-max)	37 (25-40)	37 (26-40)	38 (30-39)	0.840§
Birth weight (grams), median (min-max)	2708 (705-4270)	3045 (535-3770)	2663 (1290-3142)	0.261§
Small for gestational age, n (%)	4 (11.8)	2 (8.7)	0	0.859*
Parity, n (%)				
Single	30 (88.2)	22 (95.7)	6 (85.7)	0.561*
Multiple	4 (11.8)	1 (4.3)	1 (14.3)	
Type, n (%)				
Congenital	7 (20.6)	10 (43.5)	0	**0.042***
Acquired	27 (79.4)	13 (56.5)	7 (100)	
Prenatal diagnosis, n (%)	6 (17.6)	4 (17.4)	0	0.776*
Gestational age at diagnosis (weeks), mean (±SD)	30 (23-35)	32 (30-37)	-	0.195§
Delivery, n (%)				
Vaginal	12 (35.3)	5 (21.7)	4 (57.1)	0.212*
C-section	22 (64.7)	18 (78.3)	3 (42.9)	
Apgar score, n (%)				
1st minute < 7	14 (41.2)	15 (65.2)	0	**0.006***
5th minute < 7	8 (23.5)	9 (40.9)	0	0.088*
Endotracheal intubation at birth, n (%)	17 (56.7)	15 (71.4)	0	0.128*
Laterality, n (%)				
Unilateral	18 (52.9)	11 (47.8)	6 (85.7)	0.228*
Right	7 (38.9)	6 (54.5)	3 (50)	0.664*
Left	11 (61.1)	5 (45.5)	3 (50)	
Bilateral	16 (47.1)	12 (52.2)	1 (14.3)	0.228*
Volume, n (%)				
Small	7 (20.6)	12 (52.2)	4 (57.1)	**0.032***
Moderate	21 (61.8)	6 (26.1)	3 (42.9)	
Large	6 (17.6)	5 (21.7)	0	
Respiratory distress, n (%)	26 (76.5)	13 (56.5)	7 (100)	0.059*
Other associated effusions, n (%)	10 (29.4)	14 (60.9)	2 (28.6)	0.058*
Ascites	9 (26.5)	13 (56.5)	1 (14.3)	**0.029***
Pericardial	4 (11.8)	7 (30.4)	1 (14.3)	0.164*
Subcutaneous edema	8 (23.5)	11 (47.8)	0	**0.028***
Associated congenital malformation, n (%)				
Heart disease	13 (38.2)	2 (8.7)	3 (42.9)	**0.009***
Diaphragmatic hernia	6 (17.6)	9 (39.1)	1 (14.3)	
Esophageal atresia	6 (17.6)	0	2 (28.6)	
Others	1 (2.9)	1 (4.3)	0	
Chromosomopathy, n (%)	3 (12)	0	0	0.423*
Dysmorphic syndrome, n (%)	2 (6.3)	0	1 (14.3)	0.217*
Neonatal morbidity, n (%)				
Hyaline membrane disease	7 (21.2)	7 (31.8)	1 (16.7)	0.680*
Brochopulmonary dysplasia	3 (8.8)	4 (17.4)	2 (28.6)	0.234*
Patent ductus arteriosus	14 (41.2)	9 (39.1)	2 (28.6)	0.934*
Surgical closure	4 (28.6)	0	1 (100)	0.455*
Necrotizing enterocolitis ≥grade 2	1 (3)	2 (8.7)	0	0.694*
Intraventricular hemorrhage ≥ grade 3	1 (33.3)	1 (100)	1 (50)	0.999*
Leukomalacia periventricular	3 (9.4)	1 (4.5)	0	0.765*

Retinopathy of prematurity ≥ grade 2	2 (50)	1 (100)	0	0.999*
Sepsis	19 (55.9)	9 (39.1)	4 (57.1)	0.459*
Pneumonia	3 (9.4)	2 (9.1)	3 (42.9)	0.087*
Previous thoracic surgery, n (%)	25 (73.5)	9 (39.1)	4 (57.1)	**0.031***
Day of diagnosis after surgery, median (min-max)	6 (1-63)	4 (1-9)	3 (1-6)	0.189§
Duration of pleural effusion (days), median (min-max)	11 (1-108)	8 (2-32)	15 (1-30)	0.661§
Treatment, n (%)				
Spontaneous resolution	3 (8.8)	4 (17.4)	0	0.503*
Thoracocentesis	10 (29.4)	4 (17.4)	2 (28.6)	0.586*
Chest tube	24 (70.6)	8 (34.8)	4 (57.1)	**0.026***
Duration (days), median (min-max)	10 (1-54)	13 (2-32)	8 (1-30)	0.774§
Octreotide	12 (35.3)	0	0	**0.001***
Medium-chain triglycerides	16 (47.1)	0	0	**<0.001***
Albumin infusion	6 (17.6)	8 (34.8)	1 (14.3)	0.308*
Diuretics	14 (41.2)	15 (65.2)	1 (14.3)	**0.041***
Thoracic duct ligation	2 (5.9)	0	0	0.602*
Mechanical ventilation, n (%)	31 (91.2)	20 (87.0)	7 (100)	0.844*
Mechanical ventilation (days), median (min-max)	19 (1-96)	11 (2-89)	16 (7-57)	0.206§
Oxygen therapy, n (%)	31 (91.2)	23 (100)	7 (100)	0.484*
Oxygen therapy (days), median (min-max)	17 (1-167)	13 (1-156)	16 (10-69)	0.241§
Start of enteral feeding (days), median (min-max)	30 (14-106)	11 (8-49)	13 (13-13)	0.077§
Parenteral feeding, n (%)	29 (85.3)	21 (91.3)	7 (100)	0.616*
Parenteral feeding (days), median (min-max)	20 (1-119)	16 (2-88)	15 (12-63)	0.235§
NICU stay (days), median (min-max)	38 (1-167)	21 (3-135)	41 (12-167)	0.064§
Deceased, n (%)	11 (32.4)	8 (34.8)	3 (42.9)	0.930*

* Fisher's exact test, §Kruskal-Wallis test

Table 4 – Characteristics and demographic/clinical data of chylous pleural effusions (n=34)

	Congenital (n=7)	Acquired (n=27)	P
Gender, n (%)			
Male	5 (71.4)	19 (70.4)	0.956*
Female	2 (28.6)	8 (29.6)	
Gestational age at birth (weeks), median (min-max)	36 (30-37)	38 (25-40)	0.177§
Birth weight (grams), median (min-max)	3120 (1530-4270)	2410 (705-3865)	0.357§
Small for gestational age, n (%)	0	4 (14.8)	0.559*
Parity, n (%)			
Single	7 (100)	23 (85.2)	0.559*
Multiple	0	4 (14.8)	
Prenatal diagnosis, n (%)	6 (85.7)	0	0.999*
Gestational age at diagnosis (weeks), mean (±SD)	29.2 (±4.3)	-	-
In utero intervention, n (%)	3 (42.9)	0	**0.006***
Delivery, n (%)			
Vaginal	1 (14.3)	11 (40.7)	0.378*
C-section	6 (85.7)	16 (59.3)	
Apgar score, n (%)			
1st minute < 7	5 (71.4)	9 (33.3)	0.097*
5th minute < 7	5 (71.4)	3 (11.1)	**0.004***
Endotracheal intubation at birth, n (%)	4 (66.7)	13 (54.2)	0.672*
Thoracocentesis in delivery room, n (%)	2 (28.6)	0	**0.037***
Laterality, n (%)			
Unilateral	0	18 (66.7)	**0.002***
Right	0	7 (38.9)	0.999*
Left	0	11 (61.1)	
Bilateral	7 (100)	9 (33.3)	**0.002***
Volume, n (%)			
Small	2 (28.6)	5 (18.5)	0.841*
Moderate	4 (57.1)	17 (63.0)	
Large	1 (14.3)	5 (18.5)	
Respiratory distress, n (%)	5 (71.4)	21 (77.8)	0.999*
Other associated effusions, n (%)	5 (71.4)	4 (14.8)	**0.014***
Ascites	5 (100)	4 (100)	**0.007***
Pericardial	3 (60.0)	1 (25.0)	**0.021***
Subcutaneous edema	5 (100)	3 (75.0)	**0.004***
Associated congenital malformation, n (%)			
Heart disease	0	13 (48.1)	
Diaphragmatic hernia	0	6 (22.2)	**<0.0001***
Esophageal atresia	0	6 (22.2)	
Others	0	1 (3.7)	
Chromosomopathy, n (%)	0	3 (14.3)	0.999*
Dysmorphic syndrome, n (%)	0	2 (7.4)	0.999*
Neonatal morbidity, n (%)			
Hyaline membrane disease	1 (16.7)	6 (22.2)	0.999*
Brochopulmonary dysplasia	0	3 (11.1)	0.589*
Patent ductus arteriosus	1 (14.3)	13 (48.1)	0.198*
Surgical closure	0	4 (50)	0.999*
Necrotizing enterocolitis ≥ grade 2	0	1 (3.7)	0.999*
Intraventricular hemorrhage ≥ grade 3	0	1 (50)	0.999*
Leukomalacia periventricular	0	3 (11.5)	0.607*
Retinopathy of prematurity ≥ grade 2	0	2 (50.0)	0.999*
Sepsis	2 (28.6)	17 (63)	0.199*
Pneumonia	0	3 (11.5)	0.607*

Previous thoracic surgery, n (%)	0	25 (92.6)	**<0.0001***
Day of diagnosis after surgery, median (min-max)	0	6 (1-63)	0.999*
Duration of pleural effusion (days), median (min-max)	9 (1-30)	13 (1-108)	0.379§
Treatment, n (%)			
Spontaneous resolution	1 (14.3)	2 (7.4)	0.999*
Thoracocentesis	5 (71.4)	5 (18.5)	**0.014***
Chest tube	3 (42.9)	21 (77.8)	0.157*
Duration (days), median (min-max)	5 (2-11)	10 (1-54)	0.234§
Octreotide	2 (28.6)	10 (37.0)	0.999*
Duration (days), median (min-max)	3 (2-4)	21 (1-40)	0.121§
Medium-chain triglycerides	4 (57.1)	12 (44.4)	0.681*
Albumin infusion	2 (28.6)	4 (14.8)	0.580*
Diuretics	0	14 (51.9)	**0.026***
Thoracic duct ligation	0	2 (7.4)	0.999*
Mechanical ventilation, n (%)	5 (71.4)	26 (96.3)	**0.039¥**
Mechanical ventilation (days), median (min-max)	7 (1-19)	21 (4-96)	**0.013§**
Oxygen therapy, n (%)	5 (71.4)	26 (96.3)	**0.039¥**
Oxygen therapy (days), median (min-max)	7 (1-33)	19 (1-167)	0.071§
Start of enteral feeding (days), median (min-max)	0	30 (14-106)	0.999§
Parenteral feeding, n (%)	3 (42.9)	26 (96.3)	**0.003***
Parenteral feeding (days), median (min-max)	12 (11-38)	21 (1-119)	0.315§
NICU stay (days), median (min-max)	9 (1-48)	42 (6-167)	**0.004§**
Deceased, n (%)	3 (42.9)	8 (29.6)	0.656*

* Fisher's exact test, §Mann-Whitney U test, ¥Chi-square test

Agradecimentos

À Doutora Hercília Guimarães, orientadora desta dissertação, pela disponibilidade e apoio demonstrados desde o início do projeto, ao longo de todas as etapas do trabalho.

Ao Dr. Gustavo Rocha, co-orientador, também pela sua disponibilidade, ajuda e contribuição no desenvolvimento deste projeto.

À Dra. Filipa Flôr-de-Lima, pelo apoio imprescindível na realização da análise estatística dos dados e pela pronta disponibilidade e cooperação.

Ao Serviço de Neonatologia do Centro Hospitalar de S. João, pelo acolhimento e colaboração dos seus profissionais em geral.

ANEXOS

Normas da revista

Parecer da Comissão de Ética para a Saúde e Autorização do Conselho de Administração do Centro Hospitalar de S. João

E-mail de confirmação da submissão do artigo

Journal of Pediatric and Neonatal Individualized Medicine (JPNIM)

Author Guidelines

The Papers must be written in English or Italian and must be **original** (not published elsewhere in whole or in part).

Text

Please submit the text in a Word file.

Papers length should be generally around **20,000** characters.

All acronyms in the text should be expanded at first mention, followed by the abbreviation in parentheses.

Please use the following font: Times New Roman, 11 pt.

For paragraph formatting, please use single spacing and full justification.

Do not use boldface or underline character formatting; use italics just for technical terms or not English words. Use quotation marks just for quotations or to underline a particular word meaning.

Do not insert footnotes. Divide the text in **paragraphs** and assign a title to each part.

Abstract and keywords

For every article, authors should send:

- an abstract of **250-300 words**, and
- **6** keywords.

Abstract and keywords must be in English also for Italian articles.

Figures and tables

Figures (graphs, charts, photographs, and illustrations) and tables should be submitted separately from the text file:

- **for graphs and charts**, use Excel files;
- **for photographs and illustrations**, use JPEG, PNG or TIFF files (or, at least, PowerPoint);
- **for tables**, use Excel or Word files.

Please only use the following **fonts** in figures: **Helvetica or Arial**.

Authors should quote figures and tables in the text and should number them in the order in which they appear in the text. Each figure and table should be accompanied by a **short description**.

Figures and tables must be **original**.

Please note that editors and the publisher could evaluate the sent files overall and decide to modify the number of figures and tables.

Videos, audios and 3D illustrations

Starting from July 2014, we intend to accept also 3D illustrations, audios and videos (e.g., with slide presentations or demonstrations of clinical procedures) to integrate (as PDF-embedded

multimedia) into each kind of article, and we are planning to start a new *Video* series, featuring the explanation of medical procedures. You are welcome to send your contributions for evaluation (see more here).

If you plan to send a video, please make sure to follow these guidelines:

- **file format: .mp4 (H.264 encoded)**;
- dimensions: 645x360 or smaller.

Videos, audios and 3D illustrations must be **original**.

References

Please list the references **in order of citation** in the text, in **square brackets**.

For each entry, please clearly indicate the following data: names of **all the authors**, title of the article/book, publication year. Moreover, for journal articles, indicate journal title, volume, issue, first and last page of the article; for websites, indicate the last access; for books, indicate the book publisher and its head office. If you want to quote a chapter within a book, please add information on the chapter (title and authors). Examples:

- **article (see and follow Pub Med citations)**: Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365(9466):1231-8.
- **book**: Cowan CP, Cowan PA. When partners become parents: the big life change for couples. New York: Basic Books, 1992.
- **chapter within a book**: Eyben E. Fathers and sons. In: Rawson B (Ed.). Marriage, divorce and children in ancient Rome. Oxford: Clarendon Press, 1991.
- **website**: http://guidance.nice.org.uk/CG54, last access: April 2012.

Author Listing

For each author, please list the following items: name, surname, institutional affiliations.

To facilitate the publisher's communication with authors, please list also the e-mail addresses.

Further requirements

Please indicate a conflict of interest statement and a funding acknowledgement statement.

In case of human experimentation, please indicate which ethical standards were followed and write an informed consent statement.

In experiments on animals, please indicate an animal rights statement.

Copyright agreement

Please note that before the article final publication the corresponding author will have to send a signed copyright agreement, where he/she agree to transfer the copyright to the journal's publisher. The copyright agreement can be read here.

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

1. I acknowledge that publishing in JPNIM is **free of charge: no payments are required from the Authors.**
2. I have read the Editorial Policies.

3. The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
4. Authorship credit shall be based on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Each and every person listed as an author meets conditions 1, 2 and 3. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship.
5. All contributors who do not meet the criteria for authorship are to be listed in an Acknowledgments section at the end of the article. Financial and material support are also acknowledged.
6. No conflicts of interest exist or are clearly indicated at the end of the article.
7. The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines, which is found in About the Journal.
8. The text contains a conflict of interest statement and a funding acknowledgement statement. In case of human experimentation, the text explains which ethical standards were followed and contains an informed consent statement. In experiments on animals, the text contains an animal rights statement.
9. I authorise the processing of my personal information under the Italian Legislative Decree n° 196/2003.
10. I acknowledge that before the article final publication I will have to send a signed copyright agreement, where I agree to transfer the copyright to the journal's publisher. The copyright agreement can be read here.

CES 70-14

Exmo. Senhor

Presidente do Conselho de Administração do

Centro Hospitalar de S. João – EPE



Assunto: Pedido de autorização para realização de estudo/projecto de investigação

Nome do Investigador Principal: Mariana Marques Barbosa

Título do projecto de investigação: Neonatal Pleural Effusions in a Level III Neonatal Intensive Care Unit

Pretendendo realizar no(s) Serviço(s) de Neonatologia do Centro Hospitalar de S. João – EPE o estudo/projecto de investigação em epígrafe, solicito a V. Exa., na qualidade de Investigador/Promotor, autorização para a sua efectivação.

Para o efeito, anexa toda a documentação referida no dossier da Comissão de Ética do Centro Hospitalar de S. João respeitante a estudos/projectos de investigação, à qual endereçou pedido de apreciação e parecer.

Com os melhores cumprimentos.

Porto, 10 / Março / 2014

O INVESTIGADOR/PROMOTOR

Mariana Barbosa

Parecer

Título do Projecto: "Neonatal Pleural Effusions in a Level III Neonatal Intensive Care Unit"
Nome do Investigador Principal: Mariana Marques Barbosa

Serviço onde decorrerá o Estudo: Serviço de Neonatalogia do Centro Hospitalar de São João (CHSJ)

Objectivo do Estudo:

Determinar as principais causas, opções terapêuticas e prognóstico de derrames pleurais neonatais numa população de recém-nascidos de alto risco internados num centro de cuidados neonatais terciário.

Concepção e Pertinência do Estudo: Estudo de tipo retrospectivo, recorrendo ao levantamento de dados dos processos clínicos de doentes internados na Unidade de Cuidados Intensivos Neonatais do Hospital de S. João entre os anos de 1997 e 2014 com os diagnósticos implicados no objectivo do estudo.
A Sr.ª Directora do Serviço deu o seu aval à realização deste estudo.
Benefício/risco: Dada a natureza do estudo, não há benefícios nem riscos inerentes.
Respeito pela liberdade e autonomia do sujeito de ensaio: Dada a natureza do estudo, NA

Confidencialidade dos dados: "A todos os doentes é garantido o sigilo dos dados individuais; para esse efeito está criado um número de código identificativo cuja descodificação será única e exclusivamente do conhecimento dos investigadores do estudo. Todos os profissionais participantes no estudo ficam sujeitos ao segredo profissional".
Elo de ligação: Prof.ª Hercília Guimarães

Indemnização por danos: NA
Continuação do tratamento: NA
Propriedade dos dados: Do investigador, mas com critérios de publicação definidos
Curriculum do investigador: Adequado ao perfil da investigação.
Data previsível da conclusão do estudo: Janeiro 2015
Conclusão: Considerados os objectivos do estudo e a inerente ponderação benefício/risco, proponho um parecer favorável à realização deste projeto de investigação.

Porto e H.S.João, 2014-03-23

O Relator

Doutor Filipe Almeida

7. SEGURO

a. *Este estudo/projecto de investigação prevê intervenção clínica que implique a existência de um seguro para os participantes?*

SIM ☐ (Se sim, junte, por favor, cópia da Apólice de Seguro respectiva)
NÃO ☑
NÃO APLICÁVEL ☐

8. TERMO DE RESPONSABILIDADE

Eu, Mariana Marques Barbosa,
abaixo-assinado, na qualidade de Investigador Principal, declaro por minha honra que as informações prestadas neste questionário são verdadeiras. Mais declaro que, durante o estudo, serão respeitadas as recomendações constantes da Declaração de Helsínquia (com as emendas de Tóquio 1975, Veneza 1983, Hong-Kong 1989, Somerset West 1996 e Edimburgo 2000) e da Organização Mundial da Saúde, no que se refere à experimentação que envolve seres humanos. Aceito, também, a recomendação da CES de que o recrutamento para este estudo se fará junto de doentes que não tenham participado em outro estudo no decurso do actual internamento ou da mesma consulta.

Porto, 10 / Março / 2014

Mariana Barbosa

O Investigador Principal

PARECER DA COMISSÃO DE ÉTICA PARA A SAÚDE DO CENTRO HOSPITALAR DE S. JOÃO

emitido na reunião plenária da CES de 27 / Março / 2014

A Comissão de Ética para a Saúde APROVA por unanimidade o parecer do Relator, pelo que nada tem a opor à realização deste projecto de investigação.

Prof. Doutor Filipe Almeida
Presidente da Comissão de Ética

E-mail de confirmação da submissão do artigo

JPNIM Staff <journal@jpnim.com> 20/02

para mim

Mariana Marques Barbosa:

Thank you for submitting the manuscript, "Neonatal pleural effusions in a level III Neonatal Intensive Care Unit" to Journal of Pediatric and Neonatal Individualized Medicine (JPNIM). With the online journal management system that we are using, you will be able to track its progress through the editorial process by logging in to the journal web site:

Manuscript URL: http://www.jpnim.com/index.php/jpnim/author/submission/252
Username: marianamb013

If you have any questions, please contact us. Thank you for considering this journal as a venue for your work.

...

JPNIM Staff
Journal of Pediatric and Neonatal Individualized Medicine (JPNIM)

Journal of Pediatric and Neonatal Individualized Medicine (JPNIM)
http://www.jpnim.com